HomeFilePharmacology

Pharmacology

View Category

Coronary disease

Safety of Acetylcholine in the Cath Lab

The concepts of ischemia with non-obstructive coronary artery disease (INOCA) and myocardial infarction with non-obstructive coronary artery...
solaci -
Learn More
Antiplatelet

Results of Zotarolimus-Eluting Stents vs Biolimus-Eluting Polymer-Free Stents After 2 Years. Are They Safe in Patients at High Risk for Bleeding?

The proportion of patients treated with coronary angioplasty who are at a high risk for bleeding is...
solaci -
Learn More
Acute coronary syndromes

Prophylactic Rivaroxaban Therapy for Left Ventricular Thrombus after ST-Segment Elevation Acute Coronary Syndrome

The incidence of left ventricular thrombosis (LVT) after anterior ST-segment elevation myocardial infarction (STEMI) ranges from 4%...
solaci -
Learn More
Antiplatelet

Should Aspirin Be the Standard of Secondary Prevention of MACE?

Much has been published recently on short term dual antiplatelet therapy (DAPT) both in acute (ACS) and...
solaci -
Learn More
Antiplatelet

WOEST 2 | Dual Versus Triple Antithrombotic Scheme in the Real World.

The WOEST study found a significant reduction in bleeding complications post PCI with oral anticoagulation indication (OAC)...
solaci -
Learn More
Antiplatelet

Ticagrelor Shows Benefits in Coronary Microvascular Function after NSTEMI

Coronary microvascular disfunction (CMD) is an important long-term prognosis predictor. CMD treatment can be an effective therapeutic...
solaci -
Learn More
Antithrombotic Anticoagulants

RESTORE | Using Rivaroxaban to Prevent Radial Artery Occlusion After an Intervention

Radial access has long demonstrated its benefit, but one of its most feared complications is radial artery...
solaci -
Learn More
Antiplatelet

ACC 2022 | ADAPT-TAVR: Endoxaban Is Not Superior to DAPT After TAVR

DAPT-TAVR is a randomized trial that tested endoxaban in patients with no indication for anticoagulation who underwent...
solaci -
Learn More